Ken Huang

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

Yutaka Okawa, Teru Hideshima, Paul M. Steed et al. · Blood · 2008 · 209 citations · Full text

Medicine, Oncology, Pharmacology +16

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

Sarat Chandarlapaty, Ayana Sawai, Qing Ye et al. · Clinical Cancer Research · 2008 · 184 citations

Medicine, Medicinal Chemistry, Pharmacology +14

Pharmacokinetics and Tissue Disposition in Monkeys of an Antisense Oligonucleotide Inhibitor of Ha-Ras Encapsulated in Stealth Liposomes

Rosie Z. Yu, Richard S. Geary, Janet M. Leeds et al. · Pharmaceutical Research · 1999 · 46 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Targeting of Multiple Signaling Pathways by the Hsp90 Inhibitor SNX-2112 in EGFR Resistance Models as a Single Agent or in Combination With Erlotinib

John W. Rice, James M. Veal, Amy F. Barabasz et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2009 · 25 citations · Full text

Medicine, Oncology, Pharmacology +15